leisure time -WSS

leisure time

author：knowledge 2025-09-14 10:07:44 - browse：44

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke Thursday at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

As Cytokinetics faces pressure to sell itself to a large pharma company following positive late-stage results of its heart drug, CEO Robert Blum maintains that the biotech can launch the treatment — what would be its first approved medication — on its own.

Cytokinetics reported top-line results of its drug, aficamten, in obstructive hypertrophic cardiomyopathy, or oHCM, last December, sending its shares up on speculation the company would get acquired. Full Phase 3 results released this week further suggest the drug could be used more flexibly than a similar treatment sold by Bristol Myers Squibb, but investors have questioned whether the biotech has the resources and salesforce to compete with a large pharma company.

Blum, speaking Thursday at a talk during STAT’s Breakthrough Summit West, said that if prospective buyers approach the company, he will talk to them, but “at the same time, we’re pushing forward, as we always have, with the original intention to build a commercial business. And that’s not something new. That’s not something that’s a result of a failed M&A dialogue.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Drastic changes should bring profitability, startup health insurers say

WSS

Wegovy trial has doctors encouraged over new possibilities

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

Naloxone nonprofit donates 200,000 doses after FDA approval

Hospitals, health systems can help patients avoid medical debt

Timeline: Special counsel's probe into Trump's handling of classified documents

Drastic changes should bring profitability, startup health insurers say

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

Anavex keeps shifting the goalposts in its clinical trials

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The best solution to the drug shortages problem

State Dept. review finds Biden bears some blame for Afghanistan failures

'Hero' Louisville officer shot in head at mass shooting discharged over 3 months later

Peter Hotez and the public health issue of online harassment

Why failed clinical trials don’t always spell doom for a new drug

23andMe had bad news about my health. I wish a person had delivered it

Wayne Brady comes out as pansexual: 'Free to love whomever I want'

knowledge

Biden announces an advanced cancer research initiative

Biden jokes that Republicans may impeach him because inflation is starting to cool down

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Timeline: Special counsel's probe into Trump's handling of classified documents

Ford recalls 870K F

NIH trials fail to test meaningful long Covid therapies, experts say

leisure time

explore

Wikipedia

knowledge